Citations - Ray-Coquard Isabelle

CONCLUSIONS: PARP inhibitors play a pivotal role in the management of newly diagnosed ovarian cancer, which will affect subsequent treatment choices. Refinement of testing for patient selection and identification of regimens to treat populations that appear to benefit less from PARP inhibitors are a priority.... Read more
Published on: 2020-06-23
Source: Ray-Coquard Isabelle
By: M R Mirza
CONCLUSIONS: PARP inhibitors play a pivotal role in the management of newly diagnosed ovarian cancer, which will affect subsequent treatment choices. Refinement of testing for patient selection and identification of regimens to treat populations that appear to benefit less from PARP inhibitors are a priority.... Read more
Published on: 2020-06-23
Source: Ray-Coquard Isabelle
By: M R Mirza
CONCLUSIONS: PARP inhibitors play a pivotal role in the management of newly diagnosed ovarian cancer, which will affect subsequent treatment choices. Refinement of testing for patient selection and identification of regimens to treat populations that appear to benefit less from PARP inhibitors are a priority.... Read more
Published on: 2020-06-23
Source: Ray-Coquard Isabelle
By: M R Mirza
CONCLUSIONS: PARP inhibitors play a pivotal role in the management of newly diagnosed ovarian cancer, which will affect subsequent treatment choices. Refinement of testing for patient selection and identification of regimens to treat populations that appear to benefit less from PARP inhibitors are a priority.... Read more
Published on: 2020-06-23
Source: Ray-Coquard Isabelle
By: M R Mirza
CONCLUSIONS: PARP inhibitors play a pivotal role in the management of newly diagnosed ovarian cancer, which will affect subsequent treatment choices. Refinement of testing for patient selection and identification of regimens to treat populations that appear to benefit less from PARP inhibitors are a priority.... Read more
Published on: 2020-06-23
Source: Ray-Coquard Isabelle
By: M R Mirza
CONCLUSIONS: PARP inhibitors play a pivotal role in the management of newly diagnosed ovarian cancer, which will affect subsequent treatment choices. Refinement of testing for patient selection and identification of regimens to treat populations that appear to benefit less from PARP inhibitors are a priority.... Read more
Published on: 2020-06-23
Source: Ray-Coquard Isabelle
By: M R Mirza
CONCLUSIONS: We validated the PrOTYPE assay following the Institute of Medicine guidelines for the development of omics-based tests. This fully defined and locked-down clinical-grade assay will enable trial design with molecular subtype stratification and allow for objective assessment of the predictive value of HGSOC molecular subtypes in precision medicine applications.... Read more
Published on: 2020-06-20
Source: Ray-Coquard Isabelle
By: Aline Talhouk
BACKGROUND: Uterine sarcomas are a group of rare tumors that include different subtypes. Patients with histopathological high-grade diseases are at high-risk of recurrence or progression, and have a poor prognosis. We aim to explore the most appropriate management in patients with uterine high-grade sarcomas.... Read more
Published on: 2020-06-18
Source: Ray-Coquard Isabelle
By: Isabelle Ray-Coquard
CONCLUSION: The 30-day death rate of cancer patients with or without documented SARS-COV-2 infection is poor, but the majority of deaths occur in RT-PCR-negative patients.... Read more
Published on: 2020-06-17
Source: Ray-Coquard Isabelle
By: Souad Assaad
PURPOSE OF REVIEW: Sarcomas are a diverse group of rare solid tumors with limited treatment options for patients with advanced, inoperable disease. Cabozantinib is a tyrosine kinase inhibitor currently approved for advanced renal cell, hepatocellular, and medullary thyroid carcinoma. Cabozantinib has potent activity against a variety of kinases, including MET,... Read more
Published on: 2020-06-17
Source: Ray-Coquard Isabelle
By: Patrick Schöffski
  • Other

    Citations

  • Other

    Citations

Translate »